The discovery of VU0652957 (VU2957, Valiglurax): SAR and DMPK challenges en route to an mGlu4 PAM development candidate
作者:Joseph D. Panarese、Darren W. Engers、Yong-Jin Wu、Jason M. Guernon、Aspen Chun、Alison R. Gregro、Aaron M. Bender、Rory A. Capstick、Joshua M. Wieting、Joanne J. Bronson、John E. Macor、Ryan Westphal、Matthew Soars、Julie E. Engers、Andrew S. Felts、Alice L. Rodriguez、Kyle A. Emmitte、Carrie K. Jones、Anna L. Blobaum、P. Jeffrey Conn、Colleen M. Niswender、Corey R. Hopkins、Craig W. Lindsley
DOI:10.1016/j.bmcl.2018.10.050
日期:2019.1
This letter describes the first account of the chemical optimization (SAR and DMPK profiling) of a new series of mGlu(4) positive allosteric modulators (PAMs), leading to the identification of VU0652957 (VU2957, Valiglurax), a compound profiled as a preclinical development candidate. Here, we detail the challenges faced in allosteric modulator programs (e.g., steep SAR, as well as subtle structural changes affecting overall physiochemical/DMPK properties and CNS penetration).